Form 8-K - Current report:
SEC Accession No. 0000950170-22-016068
Filing Date
2022-08-09
Accepted
2022-08-09 16:14:25
Documents
15
Period of Report
2022-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K janx-20220809.htm   iXBRL 8-K 65755
2 EX-99.1 janx-ex99_1.htm EX-99.1 237545
3 GRAPHIC img201480580_0.jpg GRAPHIC 2925
  Complete submission text file 0000950170-22-016068.txt   474759

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20220809.xsd EX-101.SCH 2896
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20220809_pre.xml EX-101.PRE 14447
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20220809_lab.xml EX-101.LAB 17451
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT janx-20220809_def.xml EX-101.DEF 14374
9 EXTRACTED XBRL INSTANCE DOCUMENT janx-20220809_htm.xml XML 6365
Mailing Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037
Business Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037 858-750-4700
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 221148477
SIC: 2834 Pharmaceutical Preparations